SELLAS Life Sciences Announces Expedited Development Path for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Following Feedback from FDA
Agreement on new open-label randomized registrational Phase 3 study in patients in second complete remission (CR2) poised to reduce sample […]